Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Hye Won Lee; Jun Yong Park; Taegon Hong; Min Soo Park; Sang Hoon Ahn

doi:10.1016/j.cgh.2019.09.038

Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Hye Won Lee, Jun Yong Park, Taegon Hong, Min Soo Park, Sang Hoon Ahn

Department of Internal Medicine

Research output: Contribution to journal › Short survey › peer-review

12 Citations (Scopus)

Abstract

The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.¹ Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.^2–4

Original language	English
Pages (from-to)	3043-3045.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	18
Issue number	13
DOIs	https://doi.org/10.1016/j.cgh.2019.09.038
Publication status	Published - 2020 Dec

Bibliographical note

Funding Information:
Conflicts of interest This author discloses the following: S.H.A. has acted as advisor and lecturer for BMS, Gilead Sciences, MSD, AbbVie, Janssen, Assembly Biosciences, Arbutus Biopharma, GC pharma, and Ildong and has received unrestricted grant from Gilead Sciences for the investigator initiated trials. The remaining authors disclose no conflicts. Funding Supported by GC Pharma Co Ltd.

Funding Information:
Funding Supported by GC Pharma Co Ltd.

Publisher Copyright:
© 2020 AGA Institute

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2019.09.038

Cite this

@article{314fdbcdec634cfabef43ef970ea270d,

title = "Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection",

abstract = "The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4",

author = "Lee, {Hye Won} and Park, {Jun Yong} and Taegon Hong and Park, {Min Soo} and Ahn, {Sang Hoon}",

note = "Funding Information: Conflicts of interest This author discloses the following: S.H.A. has acted as advisor and lecturer for BMS, Gilead Sciences, MSD, AbbVie, Janssen, Assembly Biosciences, Arbutus Biopharma, GC pharma, and Ildong and has received unrestricted grant from Gilead Sciences for the investigator initiated trials. The remaining authors disclose no conflicts. Funding Supported by GC Pharma Co Ltd. Funding Information: Funding Supported by GC Pharma Co Ltd. Publisher Copyright: {\textcopyright} 2020 AGA Institute",

year = "2020",

month = dec,

doi = "10.1016/j.cgh.2019.09.038",

language = "English",

volume = "18",

pages = "3043--3045.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "13",

}

TY - JOUR

T1 - Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

AU - Lee, Hye Won

AU - Park, Jun Yong

AU - Hong, Taegon

AU - Park, Min Soo

AU - Ahn, Sang Hoon

N1 - Funding Information: Conflicts of interest This author discloses the following: S.H.A. has acted as advisor and lecturer for BMS, Gilead Sciences, MSD, AbbVie, Janssen, Assembly Biosciences, Arbutus Biopharma, GC pharma, and Ildong and has received unrestricted grant from Gilead Sciences for the investigator initiated trials. The remaining authors disclose no conflicts. Funding Supported by GC Pharma Co Ltd. Funding Information: Funding Supported by GC Pharma Co Ltd. Publisher Copyright: © 2020 AGA Institute

PY - 2020/12

Y1 - 2020/12

N2 - The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4

AB - The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4

UR - http://www.scopus.com/inward/record.url?scp=85090465896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090465896&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2019.09.038

DO - 10.1016/j.cgh.2019.09.038

M3 - Short survey

C2 - 31589980

AN - SCOPUS:85090465896

SN - 1542-3565

VL - 18

SP - 3043-3045.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 13

ER -

Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this